Top C-Suite Stories
FDA issues warning letters to 30 telehealth firms over GLP-1 marketing
By Kristen SmithbergThe letters, sent Feb. 20 and made public this week, cite false or misleading claims about compounded glucagon-like peptide‑1 medications on company websites.




